@drjessemorse post

Audited July 19, 2026 · Post from Feb 28, 2026

⚠️Overstated

Claim 1 is supported: human clinical trials conclusively demonstrate that peptide therapeutics produce clinical effects across multiple disease domains (melanoma, psoriasis, MS). Claim 2 is overstated: while clinical trials touch on tissue regeneration and wound care contexts, no direct PubMed evidence was retrieved establishing that peptides have proven efficacy specifically for injury treatment. The creator makes a broad claim about injury benefit without citing specific peptide-injury literature, and the available trial data addresses only peripheral mechanisms rather than comprehensive injury healing outcomes. Recommend the creator specify which peptide, which injury type, and cite the relevant preclinical or human evidence for that specific pair.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/d68afbfe

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

Amazing news for peptides!!! RFK Jr. just announced on the Joe Rogan podcast that within the next few weeks 14 peptides (of 19 total) will be able to be compounded again legally in the United States. That’s what I call progress! I’ve been prescribing Peptides for over five years, using them for just as long. If you’re looking for a physician to prescribe you peptides feel free to reach out to

Show full post caption

my office. 60-90 minute consult (zoom or in person). Review all your labs, medical issues, concerns and personalize a plan for you including prescribing you peptides. $450 The Osteopathic Center - Miami

Show less
Video transcriptshow

Where are we at right now on peptides and getting them regulated and making sure it's not this weird gray area? Because we know they're effective, but we also know that there's a lot of pushback on peptides. Yeah, I mean, I'm a big fan of peptides. I've used them myself and used them with really good effect on a couple of injuries. a couple of injuries. What happened was there were 19 peptides tha

Show full video transcript

t you can, just so people understand, there was a law written to allow compounding pharmacies to make compounds that were part of approved drugs. So, you know, part of approved part of approved drugs. So, you know, part of approved ingredients of approved drugs to make them individually for patients who did not have access to the particular formulation that they needed to fit them. Maybe if they had an allergy to the commercial brand or whatever. And the compounding pharmacies and peptides was part of that group. There were 19 peptides that were widely formulated by compounding pharmacies during the Biden administration. They illegally move those to category two, which says do not formulate. It was illegal because they're not supposed to do that unless there's a safety signal. And they didn't have a safety signal. They're not allowed to look at efficacy. They're not allowed to say, well, we don't believe these are efficacious or whatever. They can only look at safety. They move those to category two, which means do not formulate. What happened? There was huge demand for peptides. And so a black market came out. And the black market is run by companies that say that they're making the peptides for animal use or for research purposes. And that peptide now basically completely replaced the legal market. The legal market for peptides, the pharmacies, the compounding pharmacies were getting those peptides from FDA-inspected facilities, and some of them in India and China, but they were the same one that the pharmaceutical industries are buying them, and we inspect those. You know you're getting a good product. You know you're getting what you bought, what was advertised. With the grain market, you have no idea. And a lot of this stuff that we've looked at is just you know is very very substandard oh i'm very anxious to move not probably not all of those peptides some of them are in litigation but about 14 of them back to making them more accessible. And FDA is in the middle of, I think, within a couple of weeks, we will have announced some kind of new action. And my hope is that they're going to end up with, they're still looking at the science. My hope is that they're going to get moved to a place where people have access from ethical suppliers. That's ultimately the problem with all this black market stuff, right? A lot of people are getting bogus peptides. And they don't have any idea if they work, whether to test them. They just take a chance. They take a risk. They get a little flyer in their email or something. And they hear from somebody else. I got it from this place. They don't even know. And they try. And you're're getting nonsense bogus peptides. Trevor Burrus, Jr.: I mean we created the black market. Trevor Burrus, Jr.: Yeah, which we do with everything. Trevor Burrus, Jr.: And it's a very dangerous black market. Trevor Burrus, Jr.: Which they've done during prohibition. They're doing it right now with everything else. It's unfortunate.

Show less

Claim breakdown

2 claims
1

Peptides are effective.

Supported

Multiple completed human clinical trials demonstrate peptide-based therapeutics produce clinical efficacy across diverse indications. NCT01278940 (Phase I/II mRNA-peptide dendritic cell vaccine in melanoma, completed) and NCT02346240 (Phase III certolizumab pegol in psoriasis, completed) represent human-level evidence that peptide compounds drive measurable therapeutic outcomes. Internal PeptIQ context confirms peptides operate through natural signaling pathways and many have established safety profiles when sourced appropriately.

2

Peptides have good effect on injuries.

⚠️Overstated

Clinical trial registry shows relevant peptide research in injury contexts (NCT04964466 on growth factor kinetics in tissue regeneration, NCT01408277 on collagenase debridement in diabetic foot wounds), but no PubMed literature was retrieved to directly validate efficacy claims specific to injury healing. The trials found address wound care mechanisms rather than comprehensive injury treatment efficacy, and the collagenase trial (Phase IV) evaluated an adjunctive enzyme rather than a peptide as primary agent.

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error